Innovent Biologics Statistics
Total Valuation
IVBXF has a market cap or net worth of 22.09 billion. The enterprise value is 21.22 billion.
| Market Cap | 22.09B |
| Enterprise Value | 21.22B |
Important Dates
The last earnings date was Friday, August 22, 2025.
| Earnings Date | Aug 22, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 1.71B |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +3.74% |
| Shares Change (QoQ) | +3.84% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.59B |
Valuation Ratios
The trailing PE ratio is 139.75 and the forward PE ratio is 106.16.
| PE Ratio | 139.75 |
| Forward PE | 106.16 |
| PS Ratio | 13.85 |
| PB Ratio | 10.97 |
| P/TBV Ratio | 12.14 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 134.27 |
| EV / Sales | 13.21 |
| EV / EBITDA | 107.12 |
| EV / EBIT | 132.21 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.61, with a Debt / Equity ratio of 0.23.
| Current Ratio | 2.61 |
| Quick Ratio | 2.25 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | 2.29 |
| Debt / FCF | n/a |
| Interest Coverage | 13.27 |
Financial Efficiency
Return on equity (ROE) is 8.43% and return on invested capital (ROIC) is 4.49%.
| Return on Equity (ROE) | 8.43% |
| Return on Assets (ROA) | 3.44% |
| Return on Invested Capital (ROIC) | 4.49% |
| Return on Capital Employed (ROCE) | 6.49% |
| Revenue Per Employee | 257,593 |
| Profits Per Employee | 25,535 |
| Employee Count | 5,659 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 2.97 |
Taxes
In the past 12 months, IVBXF has paid 11.00 million in taxes.
| Income Tax | 11.00M |
| Effective Tax Rate | 6.50% |
Stock Price Statistics
The stock price has increased by +158.05% in the last 52 weeks. The beta is 0.24, so IVBXF's price volatility has been lower than the market average.
| Beta (5Y) | 0.24 |
| 52-Week Price Change | +158.05% |
| 50-Day Moving Average | 11.81 |
| 200-Day Moving Average | 7.27 |
| Relative Strength Index (RSI) | 62.50 |
| Average Volume (20 Days) | 124,617 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, IVBXF had revenue of 1.59 billion and earned 158.06 million in profits. Earnings per share was 0.09.
| Revenue | 1.59B |
| Gross Profit | 1.22B |
| Operating Income | 168.37M |
| Pretax Income | 169.06M |
| Net Income | 158.06M |
| EBITDA | 205.69M |
| EBIT | 168.37M |
| Earnings Per Share (EPS) | 0.09 |
Balance Sheet
The company has 1.33 billion in cash and 471.72 million in debt, giving a net cash position of 859.99 million.
| Cash & Cash Equivalents | 1.33B |
| Total Debt | 471.72M |
| Net Cash | 859.99M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 2.01B |
| Book Value Per Share | 1.23 |
| Working Capital | 1.13B |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 76.34%, with operating and profit margins of 10.56% and 9.91%.
| Gross Margin | 76.34% |
| Operating Margin | 10.56% |
| Pretax Margin | 10.60% |
| Profit Margin | 9.91% |
| EBITDA Margin | 12.90% |
| EBIT Margin | 10.56% |
| FCF Margin | n/a |
Dividends & Yields
IVBXF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.74% |
| Shareholder Yield | n/a |
| Earnings Yield | 0.72% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |